# Inselspital, Bern University Hospital / University Cancer Center Inselspital

Source: https://onco.cc/institutions/inselspital-bern/  
OnCo record `inselspital-bern` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Bern's university hospital, a high-volume radioligand therapy centre and home to the Bern Center for Precision Medicine and the SAKK trial group.

## Summary

The University Cancer Center Inselspital coordinates cancer care at Switzerland's capital university hospital. Its nuclear medicine department under Axel Rominger is one of Europe's largest PSMA and somatostatin-receptor radioligand therapy centres with a strong dosimetry programme, and Mark Rubin, co-discoverer of the TMPRSS2-ERG fusion in prostate cancer, directs the Department for BioMedical Research and the Bern Center for Precision Medicine. The hospital runs neuro-oncology and neurosurgery, thoracic and gastrointestinal surgery, haematology and CAR-T, and is a lead site for the Swiss Group for Clinical Cancer Research (SAKK), whose coordinating centre is in Bern. The Insel Gruppe covers a large catchment across the Bernese region.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: Inselspital; UCI Bern; Bern Center for Precision Medicine
- City: Bern, CH
- Type: hospital
- Website: https://www.tumorzentrum.insel.ch

## Sources

- Tumorzentrum Inselspital: https://www.tumorzentrum.insel.ch
- Bern Center for Precision Medicine: https://www.bcpm.unibe.ch
- SAKK: https://www.sakk.ch

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/), [PSMA PET](https://onco.cc/technologies/psma-pet/), [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/)
- targets: [PSMA](https://onco.cc/targets/psma/), [Somatostatin receptor 2](https://onco.cc/targets/sstr2/)
- drugs: [Lutetium-177 dotatate](https://onco.cc/drugs/lutathera/), [Lutetium-177 vipivotide tetraxetan](https://onco.cc/drugs/pluvicto/)
- institutions: [University Hospital Basel / Tumour Centre](https://onco.cc/institutions/usb-basel/), [University Hospital Zurich / Comprehensive Cancer Center Zurich](https://onco.cc/institutions/usz-zurich/)
- terms: [Dosimetry](https://onco.cc/terms/dosimetry/), [Gene fusion](https://onco.cc/terms/gene-fusion/), [Theranostics](https://onco.cc/terms/theranostics/)
- people: [Adrian Ochsenbein](https://onco.cc/people/adrian-ochsenbein/), [Daniel M. Aebersold](https://onco.cc/people/daniel-aebersold/)

---
JSON: https://onco.cc/api/v1/entities/inselspital-bern.json